



**CEDARS-SINAI**

SAMUEL OSCHIN  
COMPREHENSIVE CANCER INSTITUTE

# 5th Annual New Therapeutics in Oncology: The Road to Personalized Medicine

*Featuring The Fenmore Lectureship  
and The Redlich Lectureship*

November 4-5, 2016


---

## COURSE DIRECTORS:

*Monica Mita, MD, MSc • Alain Mita, MD, MSc  
Robert Figlin, MD • Razelle Kurzrock, MD*

## EXPLORE NEW AGENTS IN:

- *Breast Cancer*
- *Lung Cancer*
- *GI Malignancies*
- *BRCA*
- *Synthetic Lethality*
- *Immuno-oncology*



Cedars-Sinai Medical Center  
Harvey Morse Conference Center  
Los Angeles, CA 90048

*In collaboration with*

**UC San Diego**  
MOORES CANCER CENTER

For the latest course information and to register, visit [cedars-sinai.edu/oncologycme](http://cedars-sinai.edu/oncologycme)

# ACTIVITY INFORMATION

## COURSE DESCRIPTION AND STATEMENT OF NEED

This important educational activity will provide front-line and oncology clinicians, oncology nurses, pharmacists, nurse practitioners, physician assistants and pharmacists with the most current information available about new agents in oncology and the translation of the latest research to their patients. The conference will cover drug and treatment updates with a focus on new agents in breast cancer, GI malignancies and lung cancer. We will also feature a mini-symposia that will cover BRCA and synthetic lethality.

## EDUCATIONAL OBJECTIVES

- Evaluate clinical data and mechanism of action for newly approved drugs for the treatment of cancer
- Evaluate emerging clinical data regarding new agents and strategies for the treatment of advanced lung cancer, and apply clinical data to optimize patient outcomes
- Assess cancer immunotherapy treatments and their application in clinical practice based on a thorough understanding of how they work, their side effects and indications for use
- Evaluate emerging clinical data for new agents and evolving strategies for the treatment of breast cancer, and develop individualized treatment plans for patients based upon an evaluation of efficacy and safety
- Evaluate clinical data on current and emerging agents for the treatment of myeloma and hematological malignancies
- Explore and discuss the concept of DNA repair impairment due to the BRCA system alteration and its therapeutic implications
- Evaluate emerging clinical data for new agents and evolving strategies for the treatment of renal cancer, and develop individualized treatment plans for patients based upon an evaluation of efficacy and safety
- Use AJCC or other appropriate staging in clinical practice, including the use of appropriate prognostic indicators and evidence-based national guidelines used in treatment planning

## ACCREDITATION STATEMENT

Cedars-Sinai Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

## CREDIT DESIGNATION STATEMENT

Cedars-Sinai Medical Center designates this live activity for a maximum of 9.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



## NURSES

The California State Board of Registered Nursing accepts courses approved by the ACCME for category 1 credit as meeting the educational requirements for license renewal.

## POLICY ON DISCLOSURE

It is the policy of Cedars-Sinai Medical Center to ensure balance, independence, objectivity and scientific rigor in all its educational activities. Cedars-Sinai Medical Center assesses conflict of interest with its faculty, planners and managers of CME activities. Conflicts of interest that are identified are resolved by reviewing that presenter's content for fair balance and absence of bias, scientific objectivity of studies utilized in the activity, and patient care recommendations.

While Cedars-Sinai Medical Center endeavors to review faculty content, it remains the obligation of each physician or other healthcare practitioner to determine the applicability or relevance of the information provided from this course in his or her own practice.

## ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

Commercial support for this conference is pending. Companies that support this CME activity with educational grants will be acknowledged at the conference.

## SPECIAL ACKNOWLEDGMENT

Cedars-Sinai Medical Center wishes to acknowledge the generosity of the Board of Governors Clinical Research Unit for its continuous support.

Cedars-Sinai also appreciates the support received from The Fenmore Lectureship and The Redlich Lectureship. The Fenmore Lectureship was initiated in 1978 by Mr. Maxwell J. Fenmore to present conferences on Oncology. The first annual meeting was held in 1979. The Redlich Lectureship was initiated in 1980 by Freida K. and Max H. Redlich as an endowed lectureship in Hematology to honor the outstanding CSMC Medical Staff and in particular the Division of Hematology/Oncology. In 1981, Mr. Redlich passed away from a rare hematological disorder.

**BOARD OF GOVERNORS  
CLINICAL RESEARCH UNIT**



# AGENDA

## FRIDAY, NOVEMBER 4, 2016

### MINI-SYMPOSIA: BRCA AND SYNTHETIC LETHALITY

CO-CHAIRS: *Monica Mita, MD*, and *Philomena McAndrew, MD*

- 1:30-2:00 P.M. Registration
- 2:00-2:30 BRCA, synthetic lethality and its implication for breast cancer treatment *Pamela Munster, MD*
- 2:30-2:50 BRCA-ness and ovarian cancer *Beth Karlan, MD*
- 2:50-3:10 BRCA mutations and prostate cancer *Edwin Posadas, MD*
- 3:10-3:30 BRCA mutations in pancreatic cancer and other solid tumors *Andrew Hendifar, MD*
- 3:30-3:50 BRCA mutations: Implications for cancer screening and prevention *Simon Gayther, PhD*
- 3:50-4:10 Q & A
- 4:10-6:00 P.M. Reception

## SATURDAY, NOVEMBER 5, 2016

CO-CHAIRS: *Razelle Kurzrock, MD*, and *Lawrence Piro, MD*

- 7:30-8:00 A.M. Registration and breakfast
- 8:00-8:40 New drugs approved in 2015 and their mechanism of action *Alain Mita, MD*
- 8:40-8:50 Q&A
- 8:50-10:30 New Developments in Immune Therapies Mini-Symposia
- 8:50-9:20 Personalizing immune therapies *Antoni Ribas, MD*
- 9:20-9:50 Immunotherapy: Next-generation studies *Sandip Patel, MD*
- 9:50-10:20 Immune cell therapies *Dan Kaufman, MD, PhD*
- 10:20-10:40 Q&A
- 10:40-11:00 Break
- 11:00-11:20 Multiple myeloma: A new embarrassment of riches? *Robert Vescio, MD*
- 11:20-11:30 Q&A
- 11:30-12:00 New therapeutic approaches for breast cancer *Monica Mita, MD*
- 12:00-12:10 Q&A
- 12:10-1:00 P.M. Lunch

CO-CHAIRS: *Steven Piantadosi, MD, PhD, and Barry Rosenbloom, MD*

**KEYNOTE ADDRESS**

1:00-1:45 P.M.	<b>Fenmore Lecture:</b> Melanoma treatment in the era of immuno-oncology: A stand-up-to-cancer perspective	<i>Patricia LoRusso, DO</i>
1:45-2:00 P.M.	Q&A	
2:00-2:20	The evolving treatment paradigms for renal cancer	<i>Robert Figlin, MD</i>
2:20-2:30	Q&A	
2:30-3:00	Marrying genomics and immunotherapy: A perfect match	<i>Razelle Kurzrock, MD</i>
3:00-3:10	Q&A	
3:10-3:15	Break	
3:15-3:35	<b>Redlich Lecture:</b> New developments for the treatment of brain tumors	<i>Olivier Rixe, MD, PhD</i>
3:35-3:45	Q&A	
3:45-4:05	New therapeutics for lung cancer	<i>Ronald Natale, MD</i>
4:05-4:15	Q&A	
4:15-4:35	NHL and leukemia treatment: 2016 updates	<i>Ronald Paquette, MD</i>
4:35-4:45	Q & A	
4:45 P.M.	Closing remarks and adjourn	



# REGISTRATION

## 5th Annual New Therapeutics in Oncology: The Road to Personalized Medicine

FRIDAY-SATURDAY, NOVEMBER 4-5, 2016

REGISTRATION FEES	PHYSICIAN	ALLIED HEALTH PROFESSIONAL	*RESIDENT/FELLOW	INDUSTRY
Received by October 17, 2016	<input type="checkbox"/> \$155	<input type="checkbox"/> \$85	<input type="checkbox"/> \$35	<input type="checkbox"/> \$200
Received after October 17, 2016	<input type="checkbox"/> \$195	<input type="checkbox"/> \$95	<input type="checkbox"/> \$50	<input type="checkbox"/> \$225

\*Residents/fellows are eligible to attend for a reduced registration fee. In order to receive this reduced fee, please send the written proof of residency (i.e. letter from Program Director) along with your completed registration form or upload the written proof of residency online.

### REGISTRATION METHODS:

**ONLINE** registration: [cedars-sinai.edu/oncologycme](http://cedars-sinai.edu/oncologycme)

**MAIL** form to: Cedars-Sinai Medical Center

Office of Continuing Medical Education

Attn: Registration

8797 Beverly Boulevard, Suite #250

Los Angeles, CA 90048

**FAX** form to: 310-423-8596

For additional course or registration information call 310-423-5548.

Please print clearly

LAST NAME \_\_\_\_\_ FIRST NAME \_\_\_\_\_

DEGREE \_\_\_\_\_ SPECIALTY \_\_\_\_\_

ADDRESS \_\_\_\_\_

CITY \_\_\_\_\_ STATE \_\_\_\_\_ ZIP \_\_\_\_\_

PHONE \_\_\_\_\_ FAX \_\_\_\_\_

EMAIL \_\_\_\_\_

\*An email address is required to register for the conference.

CHECK ENCLOSED PAYABLE TO CSMC FOR \$ \_\_\_\_\_

PLEASE CHARGE MY CREDIT CARD  VISA  MASTERCARD  AMEX FOR \$ \_\_\_\_\_

CC NUMBER \_\_\_\_\_ CCV \_\_\_\_\_ EXP DATE \_\_\_\_/\_\_\_\_/\_\_\_\_

AUTHORIZED SIGNATURE \_\_\_\_\_

### HOW DID YOU LEARN ABOUT THIS CME ACTIVITY?

- |  |   |   |
|--|---|---|
| <input type="checkbox"/> Brochure/Other Printed Materials    | <input type="checkbox"/> Cedars-Sinai Website | <input type="checkbox"/> Email            |
| <input type="checkbox"/> Internet Search                     | <input type="checkbox"/> Colleague            | <input type="checkbox"/> Past Participant |
| <input type="checkbox"/> Internal Cedars-Sinai Communication | <input type="checkbox"/> Other _____          |   |

### CONFIRMATION

To receive a registration confirmation, please provide your email address or fax number. If you do not receive a confirmation, please call 310-423-5548 to confirm your registration.

### REFUND POLICY

All cancellations must be submitted in writing and refunds will be subject to a \$50 administrative charge. No refunds will be given after October 24, 2016. Please email cancellation request to [cme@cshs.org](mailto:cme@cshs.org). If you do not receive confirmation of your cancellation via email, please call 310-423-5548.

### CANCELLATION POLICY

Cedars-Sinai reserves the right to cancel or reschedule programs due to circumstances beyond its control or close registration when programs are oversubscribed. Registrants are advised against purchasing nonrefundable airline tickets until they receive registration confirmation. Cedars-Sinai is not responsible for penalties incurred as a result of canceled transportation costs.

# FACULTY

**\*Alain C. Mita, MD**

*Course Co-director*

Co-director, Experimental Therapeutics Program  
Associate Professor, Department of Medicine  
Division of Hematology/Oncology  
Samuel Oschin Comprehensive Cancer Institute  
Cedars-Sinai  
Los Angeles, CA

**\*Monica Mita, MD**

*Course Co-director*

Co-director, Experimental Therapeutics Program  
Associate Professor, Department of Medicine  
Division of Hematology/Oncology  
Samuel Oschin Comprehensive Cancer Institute  
Cedars-Sinai  
Los Angeles, CA

**\*Steven Piantadosi, MD, PhD**

Experimental Therapeutics Program Associate  
PHASE ONE Foundation Distinguished Chair and  
Director, Samuel Oschin Comprehensive  
Cancer Institute  
Professor, Department of Medicine  
Division of Hematology/Oncology  
Samuel Oschin Comprehensive Cancer Institute  
Professor, Department of Medicine  
Division of Hematology/Oncology  
Cedars-Sinai  
Los Angeles, CA

**\*Simon Gayther, PhD**

Cancer Biology & Therapeutics  
Graduate Research Education  
Cedars-Sinai  
Los Angeles, CA

**\*Andrew E. Hendifar, MD, MPH**

Co-Director, Pancreas Oncology  
Gastrointestinal and Neuroendocrine Malignancies  
Samuel Oschin Comprehensive Cancer Institute  
Cedars-Sinai  
Los Angeles, CA

**\*Beth Y. Karlan, MD**

Director, Women's Cancer Program, Samuel Oschin  
Comprehensive Cancer Institute  
Director, Division of Gynecologic Oncology  
Director, Gilda Radner Hereditary Cancer Program  
Board of Governors Chair in Gynecologic Oncology  
Professor, Obstetrics and Gynecology  
Cedars-Sinai  
Los Angeles, CA

**Dan Kaufman, MD, PhD**

Professor, Department of Medicine  
UC San Diego  
La Jolla, CA

**\*Robert A. Figlin, MD, FACP**

*Course Co-director*

Steven Spielberg Family Chair in Hematology-Oncology  
Professor of Medicine and Biomedical Sciences  
Director, Division of Hematology/Oncology  
Deputy Director, Samuel Oschin Comprehensive  
Cancer Institute  
Cedars-Sinai  
Los Angeles, CA

**Razelle Kurzrock, MD**

*Course Co-director*

Chief, Division of Hematology & Oncology  
Murray Professor of Medicine  
Senior Deputy Director, Clinical Science  
Director, Center for Personalized Cancer Therapy  
& Clinical Trials Office  
UC San Diego Moores Cancer Center  
La Jolla, CA

**Philomena McAndrew, MD**

Partner, Tower Hematology Oncology  
Medical Group  
Attending Staff, Department of Medicine  
Division of Hematology/Oncology  
Cedars-Sinai  
Los Angeles, CA

**Pamela Munster, MD**

Professor, Department of Medicine  
(Hematology/Oncology), UCSF  
Director, Early Phase Clinical Trials Unit  
Leader, Developmental Therapeutics Program  
UCSF Helen Diller Family Comprehensive  
Cancer Center  
San Francisco, CA

**\*Ronald Natale, MD**

Director, National Lung Cancer Research Program  
Medical Oncologist, Samuel Oschin Comprehensive  
Cancer Institute  
Cedars-Sinai  
Los Angeles, CA

**Ronald Paquette, MD**

Hematologist/Oncologist  
Blood and Marrow Transplant Program

**Sandip Patel, MD**

Assistant Professor,  
Cancer Immunotherapy Program  
Experimental Therapeutics, Thoracic Oncology  
Assistant Director, Clinical Trials Office  
Division of Hematology & Oncology and Center  
for Personalized Cancer Therapy  
UC San Diego Moores Cancer Center  
La Jolla, CA

**Lawrence D. Piro, MD**

Hematology/Oncology  
President and CEO of The Angeles Clinic  
and Research Institute  
Los Angeles, CA

*\*Samuel Oschin Comprehensive Cancer Institute Member*

**\*Edwin M. Posadas, MD**

Co-Medical Director, Urologic Oncology Center  
Clinical Director, Genitourinary Medical Oncology Program in the Samuel Oschin Comprehensive Cancer Institute  
Associate Professor, Medicine  
Cedars-Sinai  
Los Angeles, CA

**Antoni Ribas, MD, PhD**

Professor of Medicine,  
Professor of Surgery,  
Professor of Molecular and Medical Pharmacology  
Department of Medicine, Hematology & Oncology  
Ronald Reagan UCLA Medical Center  
Los Angeles, CA

**Barry E. Rosenbloom, MD**

Partner, Tower Hematology Oncology Medical Group  
Attending Staff, Department of Medicine  
Division of Hematology/Oncology  
Cedars-Sinai  
Los Angeles, CA

**Robert Vescio, MD**

Medical Director, Multiple Myeloma and Amyloidosis Program  
Samuel Oschin Comprehensive Cancer Institute  
Cedars-Sinai  
Los Angeles, CA

**VISITING FENMORE LECTURER**

**Patricia LoRusso, DO**

Professor of Medicine (Medical Oncology)  
Associate Director of Innovative Medicine  
Yale Cancer Center  
New Haven, CT

**VISITING REDLICH LECTURER**

**Olivier Rixe, MD, PhD**

Professor, Division of Hematology/Oncology  
Cancer Center Associate Director, Clinical Research  
The Dana Wood Endowed Chair in Cancer Therapeutics and Early Phase Clinical Research  
University of New Mexico Comprehensive Cancer Center  
Albuquerque, NM

*\*Samuel Oschin Comprehensive Cancer Institute Member*

# ACTIVITY DETAILS

## CONFERENCE LOCATION


Cedars-Sinai Medical Center  
Harvey Morse Conference Center  
Plaza Level, South Tower  
8701 Gracie Allen Drive  
Los Angeles, CA 90048

## PARKING

Self-parking is available in the visitor parking lots P1, P2 (George Burns Road) or P4 (Sherbourne Drive).

## HOTEL ACCOMMODATIONS

For a detailed list of hotels convenient to the medical center, please visit <https://www.cedars-sinai.edu/Patients/Patient-and-Visitor-Resources/Los-Angeles-Area-Resources/Lodging-Near-Cedars-Sinai.aspx>. When making reservations at any of these hotels, please be sure to mention that you are attending a conference at Cedars-Sinai to ensure you receive the best current reservation rate.





**CEDARS-SINAI®**

8797 Beverly Blvd., Suite 250  
Los Angeles, CA 90048

NON-PROFIT ORG.  
U.S. POSTAGE  
PAID  
Los Angeles, CA  
Permit #22328

*Register now for:*

## **5th Annual New Therapeutics in Oncology: The Road to Personalized Medicine**

**FRIDAY-SATURDAY, NOVEMBER 4-5, 2016  
CEDARS-SINAI**

---

### **EXPLORE NEW AGENTS IN:**

- Breast Cancer
- Lung Cancer
- GI Malignancies
- BRCA
- Synthetic Lethality
- Immuno-oncology

Earn up to **9.0 AMA PRA Category 1 Credits™**